Cargando…
CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
T-cell acute lymphoblastic leukemia (T-ALL), a form of T-cell malignancy, is a typically aggressive hematological malignancy with high rates of disease relapse and a poor prognosis. Current guidelines do not recommend any specific treatments for these patients, and only allogeneic stem cell transpla...
Autores principales: | Ren, Anqi, Tong, Xiqin, Xu, Na, Zhang, Tongcun, Zhou, Fuling, Zhu, Haichuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861718/ https://www.ncbi.nlm.nih.gov/pubmed/36680011 http://dx.doi.org/10.3390/vaccines11010165 |
Ejemplares similares
-
T-ALL Cells as Tool Cells for CAR T Therapy
por: Ren, Anqi, et al.
Publicado: (2023) -
CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
por: Shi, Jiangzhou, et al.
Publicado: (2021) -
The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity
por: Zhang, Shangkun, et al.
Publicado: (2022) -
Opportunities for CAR-T Cell Immunotherapy in HIV Cure
por: Campos-Gonzalez, Gerard, et al.
Publicado: (2023) -
Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL
por: Chen, Long, et al.
Publicado: (2023)